血清肿瘤标记物在间质性肺病与肺恶性肿瘤的临床应用  

Clinical Application of Serum Tumor Markers in Interstitial Lung Disease(ILD)and Lung Malignant Tumor

作　　者：沈乐[1] 白淑荣[1] Le Shen;Shurong Bai(Department of Respiratory Medicine,People's Hospital of Ningxia Hui Autonomous Region,Yinchuan,Ningxia 750000,China)

机构地区：[1]宁夏回族自治区人民医院呼吸内科,宁夏银川750000

出　　处：《西藏医药》2020年第2期17-19,共3页Tibetan Medicine

摘　　要：目的探讨血清肿瘤标记物在间质性肺病与肺恶性肿瘤的临床应用。方法收集我院2016年1月~2016年12月确诊的肺部疾病患者109例。其中,A组为间质性肺病患者54例,B组为肺恶性肿瘤患者55例,对各组血清肿瘤标记物CEA、CA125、NSE、SCC、CYFRA21-1的水平值进行分析比较。结果A组多种肿瘤标记物阳性率和水平值低于B组,组间比具有统计学意义(P<0.05)。结论ILD患者血清肿瘤标记物的水平可作为疾病严重程度的参考。Objective:To investigate the clinical application of serum tumor markers in interstitial lung disease(ILD)and lung malignant tumor.Methods:Totally,109 patients with ILD and lung malignant tumor were admitted and treated in our hospital from January 2016 to December 2016.Patients with ILD were divided into A group(n=54),while patients with lung malignant tumor were divided into B group(n=55).The levels of CEA,CA125,NSE,SCC,and CYFRA21—1 were compared between the two groups.Results:The levels of CEA,CAI25,NSE,SCC,and CYFRA21—1 in A group were significantly lower than those in B group(P<0.05).Conclusions:The serum tumor markers in interstitial lung disease(ILD)may be referred to disease severity.

关 键 词：间质性肺病 肿瘤标记物 肺恶性肿瘤 

分 类 号：R734.2[医药卫生—肿瘤] R563[医药卫生—临床医学]